Autor(es):
Roseira, J ; Ramos, J
Data: 2019
Identificador Persistente: http://hdl.handle.net/10400.17/3271
Origem: Repositório do Centro Hospitalar de Lisboa Central, EPE
Assunto(s): CHLC GAS; Adalimumab / pharmacokinetics; Adalimumab / therapeutic use; Adrenal Cortex Hormones / adverse effects; Adrenal Cortex Hormones / pharmacokinetics; Adrenal Cortex Hormones / therapeutic use; Anti-Inflammatory Agents / pharmacokinetics; Anti-Inflammatory Agents / therapeutic use; Antibodies, Monoclonal / pharmacokinetics; Antibodies, Monoclonal / therapeutic use; Certolizumab Pegol / pharmacokinetics; Certolizumab Pegol / therapeutic use; Female; Humans; Inflammatory Bowel Diseases / drug therapy; Infliximab / pharmacokinetics; Infliximab / therapeutic use; Maternal-Fetal Exchange; Placenta / metabolism; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications / drug therapy; Pregnancy Trimesters / metabolism; Tumor Necrosis Factor-alpha / antagonists & inhibitors
Descrição
INTRODUCTION: Inflammatory bowel disease activity is associated with adverse pregnancy outcomes. Anti-tumor necrosis factor α therapy is often required to treat flares and to maintain disease remission. However, there are concerns regarding treatment with these agents during pregnancy, as they actively cross the placental barrier. MATERIAL AND METHODS: Studies regarding anti-tumor necrosis factor α therapy during pregnancy were identified from PubMed from 1958 to January 2018. The reference lists of the selected studies were reviewed to identify complementary publications. RESULTS AND DISCUSSION: Anti-tumor necrosis factor α agents are efficient treatments for moderate-to-severe inflammatory bowel disease and may ensure remission during pregnancy. Although these drugs cross the placenta, they are considered safe for both the mother and the fetus. Furthermore, up-to-date guidelines support therapy continuation during pregnancy aiming for disease control. The same guidelines also consider stopping treatment during the third trimester to limit maternal-fetal drug transfer. However, data shows that this strategy does not completely prevent fetus exposure. In addition, stopping treatment incurs in risk of disease flare and threatens subsequent therapy response. Fetus drug exposure has not showed an association with adverse childhood development. However, as infant drug levels could be detected up to seven months after birth, postponement of live virus vaccination is recommended. CONCLUSION: There should be no disagreement among the medical community as to the need to maintain therapy aiming for disease remission during gestation in inflammatory bowel disease. Anti-tumor necrosis factor α agents are safe for both the mother and the fetus.
